NasdaqCM - Delayed Quote USD

Aspira Women's Health Inc. (AWH)

0.5769

-0.0414

(-6.70%)

At close: 4:00:02 PM EST

Aspira Women's Health Announces the Appointment of Mike Buhle as SVP of Commercial Operations

Aspira Women's Health Inc. ("Aspira" or the "Company") (Nasdaq:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Mike Buhle as SVP of Commercial ...

ACCESSWIRE 4 days ago

AWH
-6.70%
Aspira Women’s Health Announces Appointment of Dr. Sandra Milligan as Interim CEO

CEO Nicole Sandford will step down for personal reasons and will remain as a consultant to ensure a seamless transitionAUSTIN, Texas, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (NASDAQ: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, Chief Executive Officer (CEO) and Board member, will be departing the Company to focus on a family health matt

GlobeNewswire 29 days ago

AWH
-6.70%
Aspira Women’s Health Successfully Reaches the First Milestone of the ARPA-H $10 Million Award

The Company received the first $2 million from the ARPA-H Sprint for Women’s Health AwardAUSTIN, Texas, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (NASDAQ: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the successful completion of the first development milestone of its Advanced Research Projects Agency for Health (ARPA-H) award. As a result, Aspira has received a $2 million cash

GlobeNewswire last month

AWH
-6.70%
Aspira Womens Health Inc (AWH) Q3 2024 Earnings Call Highlights: Strategic Wins Amidst Market ...

Aspira Womens Health Inc (AWH) reports growth in test volumes and secures a $10 million federal award, despite weather-related setbacks.

GuruFocus.com last month

AWH
-6.70%
Aspira Women’s Health Reports Selected Third Quarter 2024 Financial Results

Q3 2024 OvaSuiteSM revenue of $2.3 million and volume of 6,001 units Cash utilization for the third quarter was $2.9 million, a decrease of 12% compared to the second quarter of 2024 Full year 2024 cash guidance reconfirmed as $13.0-$14.5 million Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development

GlobeNewswire last month

AWH
-6.70%
Aspira Women’s Health Expands Co-Marketing and Distribution Collaboration with BioReference® to Include OvaWatch®

BioReference team is now able to provide the entire OvaSuite portfolio to healthcare providers in New York and New JerseyAUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (NASDAQ: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the expansion of its co-marketing and distribution collaboration with BioReference Health, LLC (“BioReference”), a wholly-owned subsidiary of OPKO

GlobeNewswire 2 months ago

AWH
-6.70%
OPK
Aspira Women’s Health to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 14, 2024

Management to Announce Earnings Results and hold a call at 8:30 am ETAUSTIN, Texas, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three and nine months ended September 30, 2024, on Thursday, November 14, 2024. Management will also host a conference call

GlobeNewswire 2 months ago

AWH
-6.70%
Aspira Women’s Health Issues Letter to Shareholders and Announces Virtual Research & Development Day on October 29, 2024

Event to feature presentations from Dr. Kevin Elias, Dr. Richard Gersh, Dr. Sandra Milligan, and Dr. Todd Pappas on the Company’s development pipelineAUSTIN, Texas, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, has issued a letter to Company shareholders and announced it will host a virtual Research & Development Day on Tuesday, October 29, 20

GlobeNewswire 2 months ago

AWH
-6.70%
Aspira Women’s Health Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health

Aspira aims to develop a multi-marker miRNA blood test to aid in the detection of endometriosisAUSTIN, Texas, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it has been selected by the Advanced Research Projects Agency for Health (ARPA-H) as an awardee of the Sprint for Women’s Health to address critical unmet challenges in wome

GlobeNewswire 2 months ago

AWH
-6.70%
Aspira Women’s Health Receives Approval from New York State Department of Health for OvaWatch®

New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation (CLEP) approval allows for OvaWatch® to be marketed in New York StateAUSTIN, Texas, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it has received approval from the New York State Department of Health’s (NYSDOH) Clinical Laboratory Evaluation Progra

GlobeNewswire 2 months ago

AWH
-6.70%
Aspira Women’s Health Announces Publication of Data Demonstrating Performance of its In-Development Blood Test for the Assessment of Malignancy Risk in Patients with an Adnexal Mass

The addition of miRNA and metadata to Aspira’s existing protein assay shows promising improvements in both sensitivity and specificity for early-stage ovarian cancer in women with an adnexal massAUSTIN, Texas, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the publication of a paper in the journal Gynecologic Oncology highlight

GlobeNewswire 4 months ago

AWH
-6.70%
Aspira Women’s Health to Present at the H.C. Wainwright 26th Annual Global Investment Conference

AUSTIN, Texas, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, CEO of Aspira Women’s Health will present at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New York Palace Hotel in New York, NY. The presentation will be available on demand on Monday,

GlobeNewswire 4 months ago

AWH
-6.70%
Aspira Women’s Health Selected as a Spoke for the Investor Catalyst Hub

“Spoke” designation acknowledges Aspira’s position as an innovator in women’s health, and provides new opportunities for funding, thought leadership and networking with other healthcare industry leadersAUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it was selected as a spoke for the Investor Catalyst Hub, a

GlobeNewswire 4 months ago

AWH
-6.70%
Aspira Women’s Health Partners with Dorsata to Create New Clinical Workflow Tool for Adnexal Masses

The innovative new tool will be made available for integration into Electronic Medical Records at over 300 clinical sites serving 2,500 clinical usersAUSTIN, Texas, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today signed a definitive agreement with Dorsata, a healthcare software company, to create a protocol workflow tool for the clinical t

GlobeNewswire 4 months ago

AWH
-6.70%
Aspira Women's Health Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Aspira Women's Health ( NASDAQ:AWH ) Second Quarter 2024 Results Key Financial Results Revenue: US$2.42m (down 2.7...

Simply Wall St. 4 months ago

AWH
-6.70%
Aspira Women’s Health Reports Second Quarter 2024 Financial Results

Q2 2024 OvaSuiteSM revenue of $2.4 million and volume of 6,471 units Q2 2024 cash utilization decreased by 16% compared to Q1 2024 Full year 2024 cash guidance decreased to $13-$14.5 million Conference Call and Webcast scheduled for today at 4:30 pm ET AUSTIN, Texas, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today reported

GlobeNewswire 5 months ago

AWH
-6.70%
Aspira Women’s Health’s Announces a Poster Presentation at the 27th Annual National Association of Nurse Practitioners in Women’s Health (NPWH) Women’s Healthcare Conference

AUSTIN, Texas, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced a poster presentation at the 27th Annual National Association of Nurse Practitioner’s in Women’s Health (NPWH) Woman’s Healthcare Conference being held on September 25-28, 2024, in Chicago, IL. Presentation details are as follows: Poster:Association of the Endometrios

GlobeNewswire 5 months ago

AWH
-6.70%
Aspira Women’s Health Announces Poster Presentation at the Menopause Society’s 2024 Annual Meeting

Presentation to highlight data demonstrating OvaWatch’s performance in assessing ovarian cancer risk in pre- and post-menopausal womenAUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced a poster presentation at the upcoming Annual Meeting of The Menopause Society being held on September 10-14, 2024 in Chicago, IL. Deta

GlobeNewswire 5 months ago

AWH
-6.70%
Aspira Women’s Health to Announce Second Quarter Earnings Results and Host a Conference Call on Monday, August 12

AUSTIN, Texas, July 31, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended June 30, 2024, on Monday, August 12, 2024. Management will also host a conference call at 4:30 p.m. Eastern Time to discuss financial results and provide a corporate update.

GlobeNewswire 5 months ago

AWH
-6.70%
Aspira Women’s Health Appoints Mr. John Ragard to its Board of Directors

Mr. Ragard further strengthens the Board bringing more than 46 years of significant public equity investment and Wall Street experienceAUSTIN, Texas, July 29, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Mr. John Ragard to its Board of Directors. Mr. Ragard is an accomplished executive with extensive experience succe

GlobeNewswire 5 months ago

AWH
-6.70%

Performance Overview

Return	AWH	S&P 500
YTD	-17.59%	-1.08%
1-Year	-88.23%	+22.14%
3-Year	-97.06%	+25.41%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Aspira Women's Health Inc. (AWH)

Aspira Women's Health Announces the Appointment of Mike Buhle as SVP of Commercial Operations

Aspira Women’s Health Announces Appointment of Dr. Sandra Milligan as Interim CEO

Aspira Women’s Health Successfully Reaches the First Milestone of the ARPA-H $10 Million Award

Aspira Womens Health Inc (AWH) Q3 2024 Earnings Call Highlights: Strategic Wins Amidst Market ...

Aspira Women’s Health Reports Selected Third Quarter 2024 Financial Results

Aspira Women’s Health Expands Co-Marketing and Distribution Collaboration with BioReference® to Include OvaWatch®

Aspira Women’s Health to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 14, 2024

Aspira Women’s Health Issues Letter to Shareholders and Announces Virtual Research & Development Day on October 29, 2024

Aspira Women’s Health Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health

Aspira Women’s Health Receives Approval from New York State Department of Health for OvaWatch®

Aspira Women’s Health Announces Publication of Data Demonstrating Performance of its In-Development Blood Test for the Assessment of Malignancy Risk in Patients with an Adnexal Mass

Aspira Women’s Health to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aspira Women’s Health Selected as a Spoke for the Investor Catalyst Hub

Aspira Women’s Health Partners with Dorsata to Create New Clinical Workflow Tool for Adnexal Masses

Aspira Women's Health Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Aspira Women’s Health Reports Second Quarter 2024 Financial Results

Aspira Women’s Health’s Announces a Poster Presentation at the 27th Annual National Association of Nurse Practitioners in Women’s Health (NPWH) Women’s Healthcare Conference

Aspira Women’s Health Announces Poster Presentation at the Menopause Society’s 2024 Annual Meeting

Aspira Women’s Health to Announce Second Quarter Earnings Results and Host a Conference Call on Monday, August 12

Aspira Women’s Health Appoints Mr. John Ragard to its Board of Directors

Performance Overview